Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant (Q37452772)

20 August 2017

1 reference

title

Development of prophylactic and therapeutic vaccines using the ISCOMATRIX adjuvant (English)

1 reference

20 August 2017

1 reference

1 reference

Eugene Maraskovsky

1

1 reference

20 August 2017

Max Schnurr

2

1 reference

20 August 2017

Nick S Wilson

3

1 reference

20 August 2017

Neil C Robson

4

1 reference

20 August 2017

Jeff Boyle

5

1 reference

20 August 2017

Debbie Drane

6

1 reference

20 August 2017

language of work or name

1 reference

21 April 2009

1 reference

Immunology & Cell Biology

20 August 2017

1 reference

20 August 2017

87

1 reference

20 August 2017

5

1 reference

20 August 2017

371-376

1 reference

Iscom, a novel structure for antigenic presentation of membrane proteins from enveloped viruses.

20 August 2017

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

ISCOMATRIX adjuvant for prophylactic and therapeutic vaccines

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Recent advances in the discovery and delivery of vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

MF59 is a safe and potent vaccine adjuvant that enhances protection against influenza virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Nanotechnology in vaccine delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Taking a Toll on human disease: Toll-like receptor 4 agonists as vaccine adjuvants and monotherapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Resiquimod and other immune response modifiers as vaccine adjuvants

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

The immunogenicity of CpG-antigen conjugates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

ISCOMATRIX adjuvant induces efficient cross-presentation of tumor antigen by dendritic cells via rapid cytosolic antigen delivery and processing via tripeptidyl peptidase II.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Tumor antigen processing and presentation depend critically on dendritic cell type and the mode of antigen delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

ISCOMATRIX adjuvant for antigen delivery

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Dendritic cell maturation enhances CD8+ T-cell responses to exogenous antigen via a proteasome-independent mechanism of major histocompatibility complex class I loading

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Cross-priming for a secondary cytotoxic response to minor H antigens with H-2 congenic cells which do not cross-react in the cytotoxic assay

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Cross-presentation, dendritic cell subsets, and the generation of immunity to cellular antigens

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Generation of major histocompatibility complex class I antigens: functional interplay between proteasomes and TPPII.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Coping with loss of perfection in the MHC class I peptide repertoire

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Cancer/testis antigens: an expanding family of targets for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Differential presentation of a soluble exogenous tumor antigen, NY-ESO-1, by distinct human dendritic cell populations

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

A long, naturally presented immunodominant epitope from NY-ESO-1 tumor antigen: implications for cancer vaccine design

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

The utility of ISCOMATRIX adjuvant for dose reduction of antigen for vaccines requiring antibody responses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Therapeutic vaccines for chronic infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Synergistic DNA-MVA prime-boost vaccination regimes for malaria and tuberculosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Immune responses to ISCOM formulations in animal and primate models

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Cytotoxic T cell polyepitope vaccines delivered by ISCOMs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Characterization of hepatitis C virus core-specific immune responses primed in rhesus macaques by a nonclassical ISCOM vaccine

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

ISCOM based vaccines for cancer immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

NY-ESO-1 protein formulated in ISCOMATRIX adjuvant is a potent anticancer vaccine inducing both humoral and CD8+ t-cell-mediated immunity and protection against NY-ESO-1+ tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Induction of broad CD4+ and CD8+ T-cell responses and cross-neutralizing antibodies against hepatitis C virus by vaccination with Th1-adjuvanted polypeptides followed by defective alphaviral particles expressing envelope glycoproteins gpE1 and [...]

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

Minor but not major histocompatibility antigens of thymus epithelium tolerize precursors of cytolytic T cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

A role for dendritic cells in the priming of antigen-specific CD4+ and CD8+ T lymphocytes by immune-stimulating complexes in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

7 January 2021

The role of antigen-presenting cells and interleukin-12 in the priming of antigen-specific CD4+ T cells by immune stimulating complexes

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

7 January 2021

Short peptide sequences containing MHC class I and/or class II epitopes linked to nano-beads induce strong immunity and inhibition of growth of antigen-specific tumour challenge in mice

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

7 January 2021

Induction of lymphocyte recruitment in the absence of a detectable immune response

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

7 January 2021

Immunotherapy and chemotherapy--a practical partnership

1 reference

https://api.crossref.org/works/10.1038%2FICB.2009.21

7 January 2021

Identifiers

DOI

10.1038/ICB.2009.21

1 reference

20 August 2017

1 reference